Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Collagen overlays can inhibit leptin and adiponectin secretion but not lipid accumulation in adipocytes.

Christian SL, Pallegar NK, Brown RJ, Viloria-Petit AM.

PeerJ. 2018 Apr 27;6:e4641. doi: 10.7717/peerj.4641. eCollection 2018.

2.

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).

Golding B, Luu A, Jones R, Viloria-Petit AM.

Mol Cancer. 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4. Review.

3.

Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines.

Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Jardim-Perassi BV, Calvinho GB, Facchini MC, Viloria-Petit AM, de Campos Zuccari DAP.

Life Sci. 2017 Aug 15;183:98-109. doi: 10.1016/j.lfs.2017.06.013. Epub 2017 Jun 15.

PMID:
28624391
4.

Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells.

Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Hellmén E, Viloria-Petit AM, Zuccari DAPC.

Vet Comp Oncol. 2017 Dec;15(4):1572-1584. doi: 10.1111/vco.12303. Epub 2017 Mar 20.

PMID:
28322030
5.

Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro.

Jarad M, Kuczynski EA, Morrison J, Viloria-Petit AM, Coomber BL.

BMC Cell Biol. 2017 Jan 23;18(1):10. doi: 10.1186/s12860-017-0127-y.

6.

Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model.

Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, de Campos Zuccari DA.

J Mammary Gland Biol Neoplasia. 2017 Mar;22(1):27-41. doi: 10.1007/s10911-016-9370-7. Epub 2017 Jan 11.

PMID:
28078601
7.

Differential effect of hypoxia on early endothelial-mesenchymal transition response to transforming growth beta isoforms 1 and 2.

Doerr M, Morrison J, Bergeron L, Coomber BL, Viloria-Petit A.

Microvasc Res. 2016 Nov;108:48-63. doi: 10.1016/j.mvr.2016.08.001. Epub 2016 Aug 5.

PMID:
27503671
8.

Signalling by Transforming Growth Factor Beta Isoforms in Wound Healing and Tissue Regeneration.

Gilbert RWD, Vickaryous MK, Viloria-Petit AM.

J Dev Biol. 2016 Jun 22;4(2). pii: E21. doi: 10.3390/jdb4020021. Review.

9.

Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules.

Adham SA, Al Rawahi H, Habib S, Al Moundhri MS, Viloria-Petit A, Coomber BL.

PLoS One. 2014 Nov 17;9(11):e113103. doi: 10.1371/journal.pone.0113103. eCollection 2014.

10.

Par6 is an essential mediator of apoptotic response to transforming growth factor beta in NMuMG immortalized mammary cells.

Avery-Cooper G, Doerr M, Gilbert RW, Youssef M, Richard A, Huether P, Viloria-Petit AM.

Cancer Cell Int. 2014 Mar 1;14(1):19. doi: 10.1186/1475-2867-14-19.

11.

Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.

12.

Characterization of TGFβ signaling during tail regeneration in the leopard Gecko (Eublepharis macularius).

Gilbert RW, Vickaryous MK, Viloria-Petit AM.

Dev Dyn. 2013 Jul;242(7):886-96. doi: 10.1002/dvdy.23977. Epub 2013 Jun 5.

13.

Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration.

Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL.

Cell. 2012 Dec 21;151(7):1542-56. doi: 10.1016/j.cell.2012.11.024.

14.

Elimination of breast tumor-associated chondroitin sulfate promotes metastasis.

Prinz RD, Willis CM, Viloria-Petit A, Klüppel M.

Genet Mol Res. 2011 Dec 8;10(4):3901-13. doi: 10.4238/2011.December.8.9.

15.

Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2.

Kuczynski EA, Viloria-Petit AM, Coomber BL.

Cancer. 2011 Dec 15;117(24):5601-11. doi: 10.1002/cncr.26247. Epub 2011 Jun 20.

16.

The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression.

Viloria-Petit AM, Wrana JL.

Cell Cycle. 2010 Feb 15;9(4):623-4. Epub 2010 Mar 2. No abstract available.

PMID:
20107326
17.

A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.

Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14028-33. doi: 10.1073/pnas.0906796106. Epub 2009 Aug 10.

18.

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.

du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):904-16.

19.

In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.

Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS.

Cancer Res. 2005 Jun 15;65(12):5365-73.

20.

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.

Viloria-Petit AM, Kerbel RS.

Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):914-26. Review.

PMID:
14967451
21.

Versican/PG-M G3 domain promotes tumor growth and angiogenesis.

Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB.

FASEB J. 2004 Apr;18(6):754-6. Epub 2004 Feb 6.

PMID:
14766798
22.

Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.

Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J.

EMBO J. 2003 Aug 15;22(16):4091-102.

23.

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody.

Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A.

Int J Cancer. 2002 Oct 20;101(6):567-75.

24.

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J.

Cancer Metastasis Rev. 2001;20(1-2):79-86. Review.

PMID:
11831651
25.

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS.

Cancer Res. 2001 Jul 1;61(13):5090-101.

26.

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.

López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS.

Oncogene. 2000 Sep 21;19(40):4611-20.

27.

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

Kerbel RS, Viloria-Petit A, Klement G, Rak J.

Eur J Cancer. 2000 Jun;36(10):1248-57. Review.

PMID:
10882863
28.

Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS.

Cancer Res. 2000 Jan 15;60(2):490-8.

29.

Establishing a link between oncogenes and tumor angiogenesis.

Kerbel RS, Viloria-Petit A, Okada F, Rak J.

Mol Med. 1998 May;4(5):286-95. Review.

Supplemental Content

Loading ...
Support Center